Azido-PEG4-Val-Cit-PAB-OH
Code | Size | Price |
---|
TAR-T14453-100mg | 100mg | Enquire | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T14453-500mg | 500mg | Enquire | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20°C
Images
Documents
Further Information
Bioactivity:
Azido-PEG4-Val-Cit-PAB-OH is a 4-unit PEG ADC linker and a PEG-based PROTAC linker. It is employed for the synthesis of antibody-drug conjugates (ADCs)[1] and PROTACs[2].
CAS:
2055024-64-9
Formula:
C29H48N8O9
Molecular Weight:
652.75
Purity:
0.98
SMILES:
CC(C)[C@H](NC(=O)CCOCCOCCOCCOCCN=[N+]=[N-])C(=O)N[C@@H](CCCNC(N)=O)C(=O)Nc1ccc(CO)cc1 |@@:1|
References
An S, et al. Small-molecule PROTACs: An emerging and promising approach for the development of targeted therapy drugs. EBioMedicine. 2018 Oct;36:553-562.
Dan N, et al. Antibody-Drug Conjugates for Cancer Therapy: Chemistry to Clinical Implications. Pharmaceuticals (Basel). 2018 Apr 9;11(2). pii: E32.